Benzinga | Aug 31, 2021 06:49AM EDT

Cantor Fitzgerald Initiates Coverage On Redhill Biopharma with Overweight Rating, Announces Price Target of $22

Cantor Fitzgerald analyst Brandon Folkes initiates coverage on Redhill Biopharma (NASDAQ:RDHL) with a Overweight rating and announces Price Target of $22.